Get the Stockscreener App
58.47
1.33%
-0.745
Corcept Therapeutics Inc stock is traded at $58.47, with a volume of 108.20K.
It is down -1.33% in the last 24 hours and up +22.69% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
See More
Previous Close:
$59.21
Open:
$58.89
24h Volume:
108.20K
Relative Volume:
0.12
Market Cap:
$6.15B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
72.18
EPS:
0.81
Net Cash Flow:
$142.60M
1W Performance:
-0.27%
1M Performance:
+22.69%
6M Performance:
+86.65%
1Y Performance:
+124.96%
1-Day Range:
$57.87
$59.15
1-Week Range:
$56.57
$59.50
52-Week Range:
$20.84
$61.66
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
58.47 | 6.15B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.73 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.83 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
618.67 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.19 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.52 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Charles Schwab Investment Management Inc. Acquires 53,191 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Algert Global LLC Increases Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics' chief accounting officer sells $80,031 in stock - Investing.com India
Gary Charles Robb Takes Money Off The Table, Sells $146K In Corcept Therapeutics Stock - Benzinga
Corcept Therapeutics: A Most Promising And Compelling Biotech (NASDAQ:CORT) - Seeking Alpha
Corcept therapeutics executive sells $146,625 in stock By Investing.com - Investing.com Canada
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by Natixis Advisors LLC - Defense World
Corcept therapeutics executive sells $146,625 in stock - Investing.com India
StockNews.com Downgrades Corcept Therapeutics (NASDAQ:CORT) to Buy - Defense World
Corcept Therapeutics' chief accounting officer sells $80,031 in stock By Investing.com - Investing.com Australia
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term - MSN
Alpha DNA Investment Management LLC Invests $464,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Cerity Partners LLC Trims Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Victory Capital Management Inc. Has $1.94 Million Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Zacks Research Has Bullish Estimate for CORT FY2024 Earnings - MarketBeat
Corcept Shares Rise More Than 60% in Three Months: Here's Why - MSN
Corcept Shares Rise More Than 60% In Three Months: Here's Why - Barchart
Q4 EPS Forecast for Corcept Therapeutics Lifted by Analyst - MarketBeat
Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet - MSN
3 Reasons Growth Investors Will Love Corcept (CORT) - Yahoo Finance
Empowered Funds LLC Buys Shares of 38,541 Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy? - MSN
Connor Clark & Lunn Investment Management Ltd. Raises Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Cornercap Investment Counsel Inc. - MarketBeat
Royce & Associates LP Has $16.81 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Teva Defends Mifepristone Antitrust Case Against Corcept - Law360
Intellectus Partners LLC Purchases Shares of 54,859 Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $65.25 Average Target Price from Analysts - Defense World
Corcept Therapeutics director Daniel Swisher sells $131,736 in stock By Investing.com - Investing.com Australia
Principal Financial Group Inc. Sells 20,770 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics director Daniel Swisher sells $131,736 in stock - Investing.com
Corcept (CORT) Upgraded to Strong Buy: Here's Why - MSN
Cushing's Syndrome Market to Show a Rise During the Study Period | - openPR
Cushing's Syndrome Market Will Drive an Exponential CAGR - openPR
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
24,800 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Acquired by Versor Investments LP - MarketBeat
Wealth Enhancement Advisory Services LLC Takes $238,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Lisanti Capital Growth LLC Increases Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance
CWA Asset Management Group LLC Acquires Shares of 20,800 Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Robeco Institutional Asset Management B.V. Trims Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 8.9%Time to Buy? - MarketBeat
US Bancorp DE Purchases 12,177 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
M&G Plc Buys New Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (CORT) Soars to 52-Week High, Time to Cash Out? - MSN
New York State Teachers Retirement System Sells 17,222 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics' chief development officer sells $489,700 in stock - Investing.com India
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.04%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):